Findings

What do systematic reviews say?

3,018 questions · 3,100 findings · 369 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 774 · 25%GRADE not reported 108 · 3.5%Very low 727 · 23.5%Low 840 · 27.1%Moderate 474 · 15.3%High 177 · 5.7%

Doxycycline vs quinolones

Stool volume · Adults and children with cholera diarrhoea

1 finding from 1 review

Antimicrobial drugs for treating cholera 2014 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 435 participants
Low

Doxycycline vs quinolones

Bacteriological failure · Adults and children with cholera diarrhoea

Doxycycline may leads to higher bacteriological failure compared with quinolones (low certainty).

1 finding from 1 review

Antimicrobial drugs for treating cholera 2014 · Cochrane Headline outcomes only
RR 5.84 [2.7, 12.65]
4 studies · 386 participants
Low

Canakinumab vs triamcinolone acetonide

Pain: at 72 hours (canakinumab 150 mg) · acute gout

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 443 participants
Moderate

Canakinumab vs triamcinolone acetonide

Inflammation: participants with no swelling at 72 hours (canakinumab 150 mg) Assessed by the investigator as no swelling, mild/palpable, moderate/visible, severe/bulging beyond the joint margins · acute gout

Canakinumab probably leads to higher inflammation: participants with no swelling at 72 hours (canakinumab… compared with triamcinolone acetonide (moderate certainty).

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
RR 1.39 [1.11, 1.74]
3 studies · 523 participants
Moderate

Canakinumab vs triamcinolone acetonide

Functional disability at 3 months ‐ not measured · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Canakinumab vs triamcinolone acetonide

Health‐related quality of life ‐ not measured · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Canakinumab vs triamcinolone acetonide

Global assessment of treatment success · acute gout

Canakinumab probably leads to higher participant global assessment of response to treatment: good or… compared with triamcinolone acetonide (moderate certainty).

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
RR 1.37 [1.16, 1.61]
3 studies · 478 participants
Moderate

Canakinumab vs triamcinolone acetonide

Withdrawals due to adverse events · acute gout

Canakinumab showed no clear difference in study withdrawals due to AE (all canakinumab doses) compared with triamcinolone acetonide (low certainty).

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
RR 1.07 [0.16, 7.23]
3 studies · 654 participants
Low

Canakinumab vs triamcinolone acetonide

Risk for at least one adverse event per patient · acute gout

Canakinumab probably leads to higher participants with at least 1 AE (all canakinumab doses) compared with triamcinolone acetonide (moderate certainty).

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
RR 1.2 [1.05, 1.39]
3 studies · 654 participants
Moderate

Benzbromarone vs allopurinol

Acute gout attacks · people with chronic gout

Benzbromarone showed no clear difference in acute gout attacks compared with allopurinol (low certainty).

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
RR 3.58 [0.15, 84.13]
1 study · 55 participants
Low

Probenecid vs allopurinol

Acute gout attacks · people with chronic gout

Probenecid showed no clear difference in acute gout attacks compared with allopurinol (low certainty).

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
RR 0.96 [0.53, 1.75]
1 study · 37 participants
Low

Probenecid vs allopurinol

Serum urate normalisation ≤ 5 mg/dL (≤ 0.3 mmol/L) ‐ not measured · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Probenecid vs allopurinol

Withdrawals due to adverse events ‐ not reported · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Probenecid vs allopurinol

Total adverse events ‐ not reported · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Probenecid vs allopurinol

Pain reduction ‐ not measured · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Benzbromarone vs allopurinol

Serum urate normalisation ‐ not reported · people with chronic gout

Benzbromarone showed no clear difference in serum urate normalisation compared with allopurinol (moderate certainty).

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
RR 1.27 [0.9, 1.79]
2 studies · 101 participants
Moderate

Probenecid vs allopurinol

Function ‐ not measured · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Probenecid vs allopurinol

Tophus regression ‐ not measured · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Benzbromarone vs allopurinol

Withdrawals due to adverse events · people with chronic gout

Benzbromarone showed no clear difference in withdrawal due to adverse events compared with allopurinol (low certainty).

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
RR 1.25 [0.28, 5.62]
2 studies · 91 participants
Low

Benzbromarone vs allopurinol

Total adverse events · people with chronic gout

Benzbromarone showed no clear difference in total adverse events compared with allopurinol (low certainty).

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
RR 3 [0.64, 14.16]
1 study · 55 participants
Low